beta cell mass
Showing 1 - 25 of >10,000
type1diabetes, Type2diabetes, Pre Diabetes Trial in Parma (68Ga-exendin-4, mixed meal test)
Recruiting
- type1diabetes
- +3 more
- 68Ga-exendin-4
- mixed meal test
-
Parma, Pr, ItalyAzienda Ospedaliero Universitaria di Parma
Dec 20, 2022
Diabetes Trial in Vienna, Paris (68Ga-NODAGA-exendin-4 PET/CT)
Recruiting
- Diabetes Mellitus
- 68Ga-NODAGA-exendin-4 PET/CT
-
Vienna, Austria
- +1 more
Jun 16, 2022
Anhydroglucitol in Children With Type 1 Diabetes
Not yet recruiting
- Diabetes Mellitus, Type 1
- Measurement of blood levels of 1,5-anhydroglucitol
- (no location specified)
Oct 25, 2022
Diabetes, Diabetes, Type 2 Trial in Nijmegen (111In-DTPA-exendin-4, IRDye800CW-exendin-4)
Unknown status
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
-
Nijmegen, Gelderland, NetherlandsRadboud University Medical Center
Jan 28, 2021
Type 1 Diabetes Trial in Nijmegen (68Ga-NODAGA-Exendin-4)
Recruiting
- Type 1 Diabetes
-
Nijmegen, Gelderland, NetherlandsRadboud University Medical Center
Nov 17, 2022
Type 1 Diabetes Trial in Nijmegen, Rotterdam (gallium-68-exendin injection followed by PET/CT scan)
Recruiting
- Type 1 Diabetes Mellitus
- gallium-68-exendin injection followed by PET/CT scan
-
Nijmegen, Gelderland, Netherlands
- +1 more
Oct 8, 2020
Beta Cell Imaging in T1D a Different Glycemic Control
Terminated
- Type 1 Diabetes Mellitus
- gallium-68-exendin PET/CT
-
Nijmegen, Gelderland, NetherlandsRadboudumc
Jan 29, 2022
Diabetes, Type 1 Trial (Ketogenic diet, food delivery and education, Standard diet, food delivery and education)
Not yet recruiting
- Diabetes Mellitus, Type 1
- Ketogenic diet, food delivery and education
- Standard diet, food delivery and education
- (no location specified)
Jun 1, 2023
Atrophy Trial (CaHMB (Dietary supplement, not Drug), CaLa)
Not yet recruiting
- Atrophy
- CaHMB (Dietary supplement, not Drug)
- CaLa
- (no location specified)
May 18, 2023
Mitapivat in Subjects With Sickle Cell Disease
Enrolling by invitation
- Sickle Cell Anemia
- +7 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial
Not yet recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +5 more
- Interferon Beta-1A
- +10 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2023
Using IMC to Analyze the Impact of ICANS on Microglia
Recruiting
- ICANS, Grade Unspecified
- CAR T-Cell-Related Encephalopathy Syndrome
- There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.
-
Freiburg, Baden Württemberg, GermanyFreiburg University Medical Center
Apr 12, 2023
Sickle Cell Anemia, Beta Thalassemia Trial run by the NHLBI (radiation, drug, biological)
Recruiting
- Sickle Cell Anemia
- Beta Thalassemia
- TBI
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Pre-diabetes, Type 2 Diabetes Trial in Philadelphia (Exenatide, Sitagliptin, Glimepiride)
Completed
- Pre-diabetes
- Type 2 Diabetes
- Exenatide
- +2 more
-
Philadelphia, Pennsylvania
- +2 more
May 16, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia Trial (Miltenyi CliniMACS Prodigy ®
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +6 more
- Miltenyi CliniMACS Prodigy ® system
- (no location specified)
Mar 23, 2023
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation Trial run by the National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
- Sickle Cell Disease
- +3 more
- Alemtuzumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia Trial (Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi))
Not yet recruiting
- Leukemia
- +12 more
- Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
- (no location specified)
Mar 20, 2023
Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)
Not yet recruiting
- Hematologic Malignancy
- +21 more
- Fludarabine
- +4 more
- (no location specified)
Feb 9, 2023
Beta-Thalassemia Trial (CS-101 injection)
Not yet recruiting
- Beta-Thalassemia
- CS-101 injection
- (no location specified)
Sep 27, 2023
Colorectal Cancer (CRC), NSCLC (NSCLC) Trial (an enriched high protein and high energy oral nutrition supplement (ONS))
Not yet recruiting
- Colorectal Cancer (CRC)
- Non-small Cell Lung Cancer (NSCLC)
- an enriched high protein and high energy oral nutrition supplement (ONS)
- (no location specified)
Dec 5, 2022
Pumilio1 Expression, Sickle Cell Anemia, ß-thalassemia
Not yet recruiting
- Sickle Cell Disease, Beta Thalassemia Intermedia
- RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR
- (no location specified)
May 30, 2023
Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Not yet recruiting
- Lymphoma, B-Cell
- +6 more
- Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
-
Guayaquil, Guayas, EcuadorInstituto Oncológico Nacional Dr. Juan Tanca Marengo
Apr 27, 2023
Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for
Not yet recruiting
- Kidney Tumor
- +2 more
- (no location specified)
Feb 6, 2023